The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use?

Cancer Treatment Reviews

Volumn 21, Issue 6, 1995, Pages 513-525

  Joel, Simon ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROCARBAZINE; TUBULIN; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE; VINDESINE; VINTRIPTOL; VINXALTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; META ANALYSIS; MICROTUBULE; MITOSIS SPINDLE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARESTHESIA; REVIEW; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASMS; VINCRISTINE; VINDESINE;

EID: 0029549655     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(95)90015-2     Document Type: Article

References (75)

1. The vinca alkaloids: a new class of oncolytic agents
2. New vinca alkaloids and related compounds
3. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules
4. Correlation of biologic data with physicochemical properties among the vinca alkaloids and their congeners
5. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro
6. Mechanism of inhibition of cell proliferation by vinca alkaloids
7. Cellular uptake and tubulin binding properties of four vinca alkaloids
8. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity
9. Preclinical and clinical pharmacology of vinca aklaloids
10. Effect of microtubule-associated proteins on the interaction of vincristine with microtubules and tubulin
11. Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs
12. Phase 1 anti-cancer agents; Vindesine (desacetyl vinblastine amide sulphate)
13. Comparison of the block of fast axoplasmic transport in mammalian nerve by vincristine, vinblastine and vindesine
14. Structure-activity relationships of dimeric catharanthus alkaloids. 1. deactylvinblastine amide (vindesine) sulphate
15. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia
16. Sequential combination of methotrexate and vindesine in previously treated children with acute leukaemia
17. Clinical experience with Vindesine, 1978
18. Vindesine
19. Vindesine
20. Phase II trial with vindesine for regression induction in patients with leukaemias and haematosarcomas
21. Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivies
22. Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells
23. Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro
24. Characterisation of a vindesine-resistant human small-cell lung cancer cell line
25. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer
26. Pharmacokinetics of vindesine and vincristine in humans
27. The pharmacolinetics of [3H] vincristine in man
28. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections
29. Pharmacokinetics of vindesine bolus and infusion
30. Pharmacokinetics and metabolism of vinca alkaloids
31. Phase II trial of vindesine in patients with malignant lymphoma
32. Phase II clinical trial with vindesine for remission induction in acute leukaemia, blastic crisis of chronic myeloid leukaemia, lymphosarcoma and Hodgkin's disease: Absence of cross-resistance with vincristine
33. A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse
34. Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial
35. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse
36. Twice weekly vindesine, a phase II study in lung cancer
37. Chemotherapy of adult acute lymphoblastic leukaemia
38. Adult acute lymphocytic leukemia: critical review of current knowledge
39. Re-induction therapy in 297 children with acute lymphoblastic leukaemia in first bone marrow relapse: a Paediatric Oncology Group study
40. Combination chemotherapy for haematological relapse in adult lymphoblastic leukaemia
41. Treatment of relapsed or refractory adult acute lymphocytic leukemia
42. The treatment of acute myelogenous leukaemia in adults
43. Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia
44. Vindesine effect in myeloid leukemia
45. Vindesine, carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study
46. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
47. Chemotherapy of non-Hodgkin's Lymphomas
48. Chemotherapy of Hodgkin's disease
49. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
50. Long-term outcome of aggressive lymphoma patients (pts) treated with the LNH-84 protocol: relapsing patients may be salvaged by intensive therapy with stem cell transplantation (ITwSCT)
51. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial
52. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study
53. Vinca alkaloids in the treatment of non-small cell lung cancer
54. Single-agent chemotherapy for advanced adenocarcinoma of the lung
55. Combination chemotherapy for advanced adenocarcinoma of the lung
56. Vinorelbine
57. Is there a role for vindesine in the treatment of non-small cell lung cancer?
58. Comparison of vincristine and vindesine in the treatment of inoperable non-small cell bronchial carcinoma
59. Small cell lung cancer
60. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer
61. Small cell lung cancer 1973–1983: early prognosis and recent obstacles
62. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma
63. Phase II trial of vindesine in patients with small cell lung carcinoma
64. Vincristinecyclophosphamide, the classical two-drug regimen for small-cell lung cancer, evaluated in a randomized study with vindesine
65. Sequential chemotherapy in good-prognosis patients with small-cell lung cancer
66. Vindesine in the treatment of breast cancer
67. Vindesine in advanced breast cancer, lymphoma and melanoma
68. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion
69. Phase II study of vindesine in patients with metastatic breast cancer
70. Phase II study of vindesine in patients with advanced breast cancer
71. Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors
72. Vindesine in the treatment of metastatic breast cancer
73. A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma
74. Epirubicin or epirubicin and vindesine in advanced breast cancer